UNCY
Income statement / Annual
Last year (2024), Unicycive Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Unicycive Therapeutics, Inc.'s net income was -$36.73 M.
See Unicycive Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$675.00 K |
$951.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$675.00 K
|
$951.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
1
|
1
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$20.01 M
|
$12.90 M
|
$12.44 M
|
$6.08 M
|
$1.02 M
|
$795.00 K
|
$344.00 K
|
| General & Administrative Expenses |
$12.10 M
|
$8.55 M
|
$6.57 M
|
$2.90 M
|
$1.01 M
|
$1.17 M
|
$608.00 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$12.10 M
|
$8.55 M
|
$6.57 M
|
$2.90 M
|
$1.01 M
|
$1.17 M
|
$608.00 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$32.12 M
|
$21.45 M
|
$19.00 M
|
$8.98 M
|
$2.02 M
|
$1.96 M
|
$952.00 K
|
| Cost And Expenses |
$32.12 M
|
$21.45 M
|
$19.00 M
|
$8.98 M
|
$2.02 M
|
$1.96 M
|
$952.00 K
|
| Interest Income |
$1.26 M
|
$615.00 K
|
$0.00
|
$0.00
|
$244.00 K
|
$139.00 K
|
$168.00 K
|
| Interest Expense |
$71.00 K
|
$82.00 K
|
$6.00 K
|
$628.00 K
|
$244.00 K
|
$139.00 K
|
$0.00
|
| Depreciation & Amortization |
$428.00 K
|
$284.00 K
|
$161.00 K
|
$13.00 K
|
$2.02 M
|
$1.96 M
|
$952.00 K
|
| EBITDA |
-$36.23 M |
-$30.18 M |
-$17.89 M |
-$9.38 M |
$0.00 |
-$63.00 K |
$0.00 |
| EBITDA Ratio |
0
|
-44.71
|
-18.81
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-30.78
|
-18.98
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$4.61 M
|
-$9.77 M
|
-$6.00 K
|
-$1.04 M
|
-$244.00 K
|
-$202.00 K
|
-$168.00 K
|
| Income Before Tax |
-$36.73 M
|
-$30.54 M
|
-$18.06 M
|
-$10.02 M
|
-$2.26 M
|
-$2.17 M
|
-$1.12 M
|
| Income Before Tax Ratio |
0
|
-45.25
|
-18.99
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$36.73 M
|
-$30.54 M
|
-$18.06 M
|
-$10.02 M
|
-$2.51 M
|
-$2.30 M
|
-$1.12 M
|
| Net Income Ratio |
0
|
-45.25
|
-18.99
|
0
|
0
|
0
|
0
|
| EPS |
-5.6 |
-1.28 |
-1.2 |
-8.6 |
-0.16 |
-0.27 |
-0.14 |
| EPS Diluted |
-5.6 |
-1.28 |
-1.2 |
-8.6 |
-0.16 |
-0.27 |
-0.14 |
| Weighted Average Shares Out |
$6.70 M
|
$2.45 M
|
$1.51 M
|
$1.17 M
|
$1.52 M
|
$842.50 K
|
$794.32 K
|
| Weighted Average Shares Out Diluted |
$6.70 M
|
$2.45 M
|
$1.51 M
|
$1.17 M
|
$1.52 M
|
$847.15 K
|
$794.32 K
|
| Link |
|
|
|
|
|
|
|
